These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27738953)

  • 1. The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.
    Weers J; Clark A
    Pharm Res; 2017 Mar; 34(3):507-528. PubMed ID: 27738953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
    Grant AC; Walker R; Hamilton M; Garrill K
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do all dry powder inhalers show the same pharmaceutical performance?
    Taylor A; Gustafsson P
    Int J Clin Pract Suppl; 2005 Dec; (149):7-12. PubMed ID: 16279997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
    Henriet AC; Marchand-Adam S; Mankikian J; Diot P
    Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inhalation characteristics of patients when they use different dry powder inhalers.
    Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
    J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy.
    González-Torralba F; Baloira A; Abad A; Fuster A; García-Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1005-1015. PubMed ID: 35547784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ellipta
    Jones TL; Neville DM; Chauhan AJ
    Ther Deliv; 2018 Feb; 9(3):169-176. PubMed ID: 29424288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Easyhaler--ideal dry powder inhaler].
    Andrzej E; Małgorzata BE
    Pol Merkur Lekarski; 2010 Apr; 28(166):307-10. PubMed ID: 20491343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices.
    Lavorini F; Mannini C; Chellini E; Fontana GA
    Drugs Aging; 2016 Jul; 33(7):461-73. PubMed ID: 27216613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry powder inhalers: an overview.
    Atkins PJ
    Respir Care; 2005 Oct; 50(10):1304-12; discussion 1312. PubMed ID: 16185366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ambulatory criteria of dry powder inhaler selection based on peak inspiratory flow recordings].
    Droszcz W; Droscez P
    Pneumonol Alergol Pol; 2002; 70(9-10):490-5. PubMed ID: 12710102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers.
    Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Nabil Salem M; Rabea H; Abdelrahim MEA
    Exp Lung Res; 2018; 44(4-5):211-216. PubMed ID: 30346848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of dry powder inhalers to improve patient outcomes: it's not just about the device.
    Weers JG
    Expert Opin Drug Deliv; 2024 Mar; 21(3):365-380. PubMed ID: 38630860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler.
    Geller DE
    Respir Care; 2005 Oct; 50(10):1313-21; discussion 1321-2. PubMed ID: 16185367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.